Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Pharmaust Limited ( (AU:NUZ) ).
Neurizon Therapeutics Limited has announced the issuance of unquoted equity securities, including options and performance rights, as part of an employee incentive scheme. This move, which involves a significant number of securities, indicates the company’s efforts to motivate and retain its workforce, potentially impacting its operational dynamics and aligning employee interests with long-term company goals.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.52 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Average Trading Volume: 416,655
Technical Sentiment Signal: Sell
Current Market Cap: A$69.49M
See more data about NUZ stock on TipRanks’ Stock Analysis page.